Aparito is the proud recipient of the EURORDIS Company Award for Health Technology at the 2022 EURORDIS Black Pearl Awards!
This award is great recognition from the rare disease community to acknowledge that Aparito makes a difference in the rare disease space.
Aparito has dedicated the last seven years to creating change in the clinical trial experience for patients living with a rare disease by developing standardised at-home assessments and using technology to convey what’s really important to patients.
EURORDIS is an extremely important organisation to Aparito because of the heritage of the previous winners and the esteemed company in which we find ourselves. EURORDIS’ innovative nature in pushing boundaries and acknowledging that the existing ways of working don’t work for the rare disease communities has been an instrumental enabler to change the status quo.
On behalf of everyone at Aparito we graciously accept this award and thank the judges, EURORDIS, and the patient communities that enable us to continue our mission to enable more patient-centric clinical trials.
This award is on behalf of the whole team at Aparito; all of our colleagues are key contributors to the success of our mission. But most importantly, this award is on behalf of all the patient communities that have trusted us to collaborate with them over the last seven years. Without you, our efforts would be nothing and for that, we are extremely grateful.Dr Elin Haf Davies, CEO of Aparito
We see the award as an incentive to improve and it’s a wonderful way to reinforce our patient engagement practices. Through co-creation, we aim to develop solutions that serve the needs of the patient community and make decentralised trials a realityDr Elisa Ferrer Mallol, Patient Advocacy Manager at Aparito
EURORDIS congratulates Aparito for the company’s collaborative approach across rare diseases, engaging patient organisations, clinicians and sponsors.EURORDIS awarding committee
Aparito’s mission is to digitise clinical trials and accelerate drug development for patients living with life-limiting diseases by supporting patient-centric clinical trials for those needing access to innovative treatments.
Aparito’s vision is that clinical trials will be conducted within patients’ homes by leveraging our Atom5™ platform incorporating disease-specific smartphone apps and integrating wearable technology to deliver virtual clinical trials.
Alexander Guest – Head of Marketing, Aparito
E-Mail: email@example.com Tel: +44 1978 896 191